Evidence map›Paper›PMID 32575507›Full record

ReviewInternational journal of molecular sciences2020

Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer.

Ginette S Santiago-Sánchez, Valentina Pita-Grisanti, Blanca Quiñones-Díaz, Kristyn Gumpper, Zobeida Cruz-Monserrate, Pablo E Vivas-Mejía

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05568433 (New Biomarkers in the Intracystic Liquid of Cystic Pancreatic Lesions), which is not on this map. Cited by 111 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 2 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05568433 completednot on this map

New Biomarkers in the Intracystic Liquid of Cystic Pancreatic Lesions

TypeobservationalSponsorIuliu Hatieganu University of Medicine and PharmacyRan2018 to 2020Enrolled63ConditionsPancreatic CystArmsEndoscopic ultrasound fine needle aspiration (EUS-FNA)
3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Mr BMT Achieves Systemic Macrophage Replacement With Preservation of Tissue Homeostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Suppression of NGALR impedes TNBC cell survival, proliferation, invasion, and migration through Akt/mTOR and JAK/STAT3 pathway inhibition.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  9. Article
  10. Review
  11. Beyond olfaction: New insights into human odorant binding proteins.Protein science : a publication of the Protein Society · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ginette S Santiago-SánchezDepartment of Biochemistry, University of Puerto Rico, Medical Sciences Campus, San Juan 00936, Puerto Rico.
Valentina Pita-GrisantiDepartment of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0002-0291-2017
Blanca Quiñones-DíazDepartment of Biochemistry, University of Puerto Rico, Medical Sciences Campus, San Juan 00936, Puerto Rico.ORCID 0000-0003-0312-671X
Kristyn GumpperDepartment of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Zobeida Cruz-MonserrateDepartment of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0003-0849-655X
Pablo E Vivas-MejíaDepartment of Biochemistry, University of Puerto Rico, Medical Sciences Campus, San Juan 00936, Puerto Rico.ORCID 0000-0002-2001-857X
The Ohio State University Wexner Medical Center · USUniversity of Puerto Rico, Medical Sciences Campus · PR

Funding

UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SHARON Hermes GIORDANO, REYNOLD Eugenio LOPEZ-ENRIQUEZ · 2002 to 2026
$36.9M
Upstream Regulation and Downstream effectors of c-MYC in Ovarian CancerU54MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Carmen M Velez Vega · 2017 to 2026
$35.8M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHARON Hermes GIORDANO · 2002 to 2026
$23.8M
Role of Lipocalin 2 in Pancreatic CancerR01CA223204 · NCI · OHIO STATE UNIVERSITY · PI CRUZ-MONSERRATE, ZOBEIDA · 2018 to 2022
$1.9M
NCI NIH HHS R01 CA223204NCI NIH HHS R01CA223204NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NIGMS NIH HHS R25 GM061838NIGMS NIH HHS R25-GM061838NIMHD NIH HHS U54 MD007600NIMHD NIH HHS U54-MD007600
6 · The paper itself

Abstract

Lipocalin-2 (LCN2) is a secreted glycoprotein linked to several physiological roles, including transporting hydrophobic ligands across cell membranes, modulating immune responses, maintaining iron homeostasis, and promoting epithelial cell differentiation. Although LNC2 is expressed at low levels in most human tissues, it is abundant in aggressive subtypes of cancer, including breast, pancreas, thyroid, ovarian, colon, and bile duct cancers. High levels of LCN2 have been associated with increased cell proliferation, angiogenesis, cell invasion, and metastasis. Moreover, LCN2 modulates the degradation, allosteric events, and enzymatic activity of matrix metalloprotease-9, a metalloprotease that promotes tumor cell invasion and metastasis. Hence, LCN2 has emerged as a potential therapeutic target against many cancer types. This review summarizes the most relevant findings regarding the expression, biological roles, and regulation of LCN2, as well as the proteins LCN2 interacts with in cancer. We also discuss the approaches to targeting LCN2 for cancer treatment that are currently under investigation, including the use of interference RNAs, antibodies, and gene editing.

Indexed as

Up-RegulationAntineoplastic Agents, ImmunologicalCell ProliferationGene EditingGene Expression Regulation, NeoplasticHumansLipocalin-2Matrix Metalloproteinase 9Molecular Targeted TherapyNeoplasm InvasivenessNeoplasm MetastasisNeoplasmsRNA, Small InterferingAntineoplastic Agents, ImmunologicalLCN2 protein, humanLipocalin-2Matrix Metalloproteinase 9MMP9 protein, humanRNA, Small InterferingcancerLCN2-MMP-9lipocalin 2NGALoncogenesiderophore

Identifiers

PMID32575507
PMCPMC7352275
OpenAlexW3035973123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.